Allogene Therapeutics (ALLO) EBITDA (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of EBITDA data on file, last reported at -$46.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 29.3% year-over-year to -$46.1 million; the trailing twelve-month figure through Mar 2026 stood at -$190.2 million (up 29.26% YoY), and the FY2025 full-year result was -$209.3 million, up 23.38% from the prior year.
• EBITDA declined to -$46.1 million in Q1 2026, from -$42.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$42.4 million in Q4 2025 to a low of -$99.1 million in Q1 2023.
• A 5-year average of -$70.1 million and a median of -$71.4 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 5747.04% in 2022 and jumped 37.44% in 2025, its largest moves.
• Tracing ALLO's EBITDA over 5 years: stood at -$96.4 million in 2022, then rose by 11.71% to -$85.1 million in 2023, then advanced by 28.93% to -$60.5 million in 2024, then advanced by 29.9% to -$42.4 million in 2025, then fell by 8.7% to -$46.1 million in 2026.
• Business Quant data shows ALLO's EBITDA at -$46.1 million in Q1 2026, -$42.4 million in Q4 2025, and -$44.9 million in Q3 2025.